CDSCO approves Trastuzumab Deruxtecan for first-line HER2-positive breast cancer EP News Bureau Jun 11, 2026 Approval expands indication for Trastuzumab Deruxtecan in combination with Pertuzumab for adults with unresectable or metastatic…
Daiichi Sankyo will remain dominant in ADC market for oncology treatments: GlobalData EP News Bureau Aug 7, 2023 By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion
Glenmark reduces cost of Trastuzumab treatment in India EP News Bureau Jun 15, 2023 A 440 mg vial of Trumab will be priced at Rs 15,749, which makes it the most affordable option available currently in the country
